Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment crawled date : 2021 - 06 - 03 save search
Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
Published: 2021-06-03 (Crawled : 22:00) - globenewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.17%
H: 0.63%
C: -0.04%
CHRS | $2.03 -6.88% -7.39% 720K
|
Health Technology
|
| O: 7.36%
H: 1.43%
C: -5.21%
treatment therapy
New Phase 3 Data at WCPGHAN Show Long-Term Safety, Tolerability, and Treatment Benefits of Bylvay™ (odevixibat) in PFIC
Published: 2021-06-03 (Crawled : 21:00) - globenewswire.com
ALBO | $44.15 -0.23% 0.39% 1.2M
|
Health Technology
|
| O: 0.0%
H: 2.16%
C: -1.61%
treatment phase 3
Kintara Therapeutics Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 for Adjuvant Treatment of Brain Tumors
Published: 2021-06-03 (Crawled : 14:15) - biospace.com/
KTRA | $0.1374 3.54% 3.42% 5.8M
|
Distribution Services
|
| O: 0.0%
H: 3.8%
C: -1.27%
treatment phase 2 trial enroll train
IGM Biosciences Announces Expansion of IgM Platform into Infectious Diseases, Publication of Preclinical Data in Nature Demonstrating Engineered IgM Antibody Antiviral Activity for the Treatment and Prevention of COVID-19
Published: 2021-06-03 (Crawled : 14:00) - igmbio.com
IGMS | $7.95 3.25% 3.14% 690K
|
Health Technology
|
| O: 1.77%
H: 11.4%
C: 6.85%
covid disease treatment infectious disease expansion antiviral antibody preclinical pre-clinical
PDS Biotechnology Expands VERSATILE-002 study of PDS0101 and KEYTRUDA® in Advanced Head and Neck Cancer to Include Patients Who Have Failed Prior Treatment with Checkpoint Inhibitors
Published: 2021-06-03 (Crawled : 13:00) - globenewswire.com
PDSB | $3.26 1.88% 1.84% 450K
|
Health Technology
|
| O: -1.59%
H: 5.21%
C: 1.62%
treatment cancer biotech technology iot keytruda
ALK Acquires OTIPRIO® (ciprofloxacin otic suspension), Broadening Treatment Solutions for Healthcare Providers and Patients
Published: 2021-06-03 (Crawled : 12:15) - prnewswire.com
OTIC | $0.077
|
Health Technology
|
| O: -1.27%
H: 2.14%
C: 0.0%
treatment
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia
Published: 2021-06-03 (Crawled : 12:15) - biospace.com/
ARWR | $23.285 -2.08% -2.13% 810K
|
Health Technology
|
| O: 0.18%
H: 0.65%
C: 0.21%
treatment phase 2 phase 2b
Achieve Announces Allowance of U.S. Patents for Dosing and Administration of Cytisinicline for the Treatment and Prevention of Addiction
Published: 2021-06-03 (Crawled : 12:00) - biospace.com/
ACHV | $4.53 0.67% 0.66% 32K
|
Health Technology
|
| O: 0.98%
H: 5.6%
C: 3.53%
treatment patent
MannKind Announces Data Presentation At 14th International Conference On Advanced Technologies & Treatments For Diabetes (ATTD 2021) To Be Held Virtually June 2-5
Published: 2021-06-03 (Crawled : 12:00) - biospace.com/
MNKD | $4.19 0.72% 0.72% 1.8M
|
Health Technology
|
| O: 1.08%
H: 2.4%
C: 1.33%
presentation diabetes treatment conference
Lilly Reveals Critical Barriers to Optimal Migraine Care and Insights From Novel Clinical and Patient-Centric Real-World Evidence, Supporting Lilly's Preventive and Acute Treatment Portfolio at AHS 2021
Published: 2021-06-03 (Crawled : 11:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.07%
H: 2.34%
C: 1.86%
treatment migraine
Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application ANAVEX®2-73 (blarcamesine) for the Treatment of Cardiac Dysfunctions
Published: 2021-06-03 (Crawled : 11:00) - anavex.com
AVXL | $3.4 -7.61% -8.24% 2M
|
Health Technology
|
| O: -0.61%
H: 5.41%
C: 4.72%
treatment life science patent anavex®2-73 anavex application
FDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
Published: 2021-06-03 (Crawled : 07:00) - globenewswire.com
AMYT | News | $14.7 0.0% 2.4M
|
Health Technology
|
| O: 0.94%
H: 4.59%
C: 0.94%
new drug treatment fda leo drug oleogel-s10 application granted grant
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.